Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Kwolek

Vascular Surgery Boston, MA Medical Doctor

NPI 1689665309 CMS profile 30475

15 Parkman St, Wac 458, Boston, MA 02114

Open in the dashboard

General payments

$55,371

232 records reported · program years 2019–2025

Research payments

$12,752

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$401,967 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Christopher Kwolek of Boston, MA is reported in the CMS Open Payments database as having received $55,371 across 232 general payments and $12,752 in research payments paid to them. Separately, studies naming them as principal investigator received $401,967 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,400 36
2024 General $11,580 36
2023 General $8,880 51
2022 General $3,883 41
2021 General $12,215 39
2021 Research $12,752 1
2020 General $9,396 6
2019 General $7,017 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Kwolek
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Christopher Kwolek were reported at $2,400. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Christopher Kwolek Vascular Surgery median Middle half National median
2019 $7,017 $796 $226–$2,363 $163
2020 $9,396 $348 $118–$1,110 $114
2021 $12,215 $471 $158–$1,421 $132
2022 $3,883 $725 $222–$2,183 $149
2023 $8,880 $836 $257–$2,440 $160
2024 $11,580 $909 $252–$2,619 $164
2025 $2,400 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endologix, Inc. $23,807 46 payments
  2. Philips Electronics North America Corporation $14,709 32 payments
  3. Silk Road Medical, Inc. $6,849 21 payments
  4. Cordis US Corp. $2,600 9 payments
  5. Medtronic, Inc. $1,486 19 payments
  6. AngioDynamics, Inc. $756 2 payments
  7. Veryan Medical Incorporated $729 10 payments
  8. Boston Scientific Corporation $522 8 payments
  9. Pfizer Inc. $510 18 payments
  10. Bolton Medical Inc $452 3 payments
  11. Other $2,952 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $28,050 14 payments
  2. Food and Beverage $13,735 200 payments
  3. Honoraria $7,800 1 payment
  4. Travel and Lodging $5,053 16 payments
  5. Long term medical supply or device loan $733 1 payment
Products named General payments · program years 2019–2025
  1. Alto Abdominal Stent Graft System $9,474 10 payments
  2. (7881) US Und $7,800 1 payment
  3. AFX $7,142 2 payments
  4. (9520) IGT Devices Undivided $5,200 1 payment
  5. ENROUTE 0.014 Guidewire $3,915 8 payments
  6. ENROUTE Transcarotid Stent System $3,915 8 payments
  7. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $3,915 8 payments
  8. ENHANCE Transcarotid Peripheral Access Kit $3,915 8 payments
  9. ENROUTE Transcarotid Stent $2,934 13 payments
  10. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $2,934 13 payments
  11. Other $17,865 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Veryan Medical Incorporated $12,752 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

25

Median for Vascular Surgery: 122

Drug cost

$280

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 25 $280

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$556,049

Medicare's payments for the services billed

Medicare patients

421

Average age 78

Services billed

1,658

184 women, 237 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 49%
Chronic kidney disease 42%
Diabetes 35%
Depression 28%
Atrial fibrillation 26%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $108
$108 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $20
$20 — —
DefenCath
  • CorMedix Inc. $18
$18 — —
NURTEC ODT
  • PFIZER INC. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record